Antinuclear Antibodies in Patients on Medication with Cardiovascular Drugs and Antihyperglycemic Agents / 임상검사와정도관리

ABSTRACT

BACKGROUND: This study was set to determine the antinuclear antibody (ANA) frequency and fluorescence pattern, as well as the incidence of drug-induced lupus (DIL) in patients on long term medications with cardiovascular drugs and antihyperglycemic agents. METHODS: Sera from 301 patients on medications with cardiovascular drugs or antihyperglycemic agents for at least 6 months and 105 serum samples from healthy controls were tested by indirect immunofluorescence on immunotype (IT)-1 cells, and the medical records were retrospectively reviewed. The patients included 39 on digoxin, 38 on theophylline, 8 on theophylline and digoxin, 26 on captopril, 15 on diltiazem, and 182 on antihyperlycemic agents. RESULTS: ANA was positive in 3 of the 105 normal controls (3%). Thirty four percent of patients on medication with digoxin, 29% on theophylline, 31% on captopril, 7% on diltiazem, and 8% on antihyperglycemic agents were positive for ANA. The prominent ANA pattern was cytoplasmic type in patients on digoxin and theophylline, and the speckled type in captopril, however, most of them showed low titers. CONCLUSIONS: Long-term ingestion of theophylline, digoxin, captopril were shown to influence ANA, but not for diltiazem and antihyperglycemics. Therefore, patients on long-term medications with theophylline, digoxin, captopril should be regularly tested for ANA.